Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
National Cancer Center, Korea Pfizer |
---|---|
Information provided by: | National Cancer Center, Korea |
ClinicalTrials.gov Identifier: | NCT00620347 |
Chemotherapy is the primary treatment option for patients with small cell lung cancer, leading to a 5-year survival of about 20% in limited disease (LD), and less than 5% in extensive disease (ED). Although initial tumor response rate to chemotherapy is very high (up to 96% for LD and up to 65% in ED), SCLC relapses in approximately 4 months in ED and 12 months in LD adn despite the administration of second-line chemotherapy, the overall median survival of patients with limited and extensive disease is approximately 18 and 9 months, respectively. In the setting of second-line therapy, response rates to chemotherapy range between 15 and 25%, with median survival in the range of 4-6 months. Second-line therapeutic options include cyclophosphamide, doxorubicin and vincristine (CAV) given every 3 weeks or topotecan, which have similar response rates, time to progression and survival in the two treatment arms (topotecan 24%, 13 and 24.7 weeks; CAV 18%, 12 and 22 weeks, respectively). However, both treatments however have substantial toxicities, with 9% of patients on trial withdrawing for toxicity reasons. Treatment-associated mortality was as high as 4.7% (possibly and definitely related), and many patients required transfusion support. Thus, while these treatments have acceptable activity second-line, more active and less toxic treatments are required for this patient population.Tyrosine kinase inhibitors have become a promising new class of anti-cancer agents owing to the importance of their targets in tumor proliferation, survival (apoptosis), angiogenesis, motility, and metastasis Among the most important receptor tyrosine kinases that regulate tumor angiogenesis are the vascular endothelial growth factor receptor 2 (VEGFR2/Flk-1/KDR), PDGFR, and the fibroblast growth factor (FGF) receptor family. These receptors belong to the split-kinase domain superfamily, which also includes Kit, the receptor for stem cell factor (SCF). Kit is frequently expressed in multiple hematologic and non-hematologic malignancies. It can also be activated in an autocrine fashion by coexpression with SCF, as is the case in SCLC, where approximately 70% of tumors and cell lines coexpress Kit and SCF at some level. Inhibition of Kit using small molecule inhibitors results in growth inhibition of multiple SCLC cell lines. Sunitinib, a novel small molecule receptor tyrosine kinase inhibitor with direct antitumor as well as antiangiogenic activity via targeting the vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), KIT, and FLT3 receptor tyrosine kinases, which showed anti-tumor activity in mouse xenograft model of SCLC. Therefore, the investigators will conduct a phase II trial to evaluate the efficacy and toxicity of Sunitinib in patients with recurrent SCLC.
Condition | Intervention | Phase |
---|---|---|
Lung Cancer |
Drug: sunitinib |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Open Label, Active Control, Single Group Assignment, Safety/Efficacy Study |
Official Title: | A Phase II Study of Sunitinib as a Second-Line Treatment for Patients With Extensive-Disease Small Cell Lung Cancer (ED-SCLC) |
Estimated Enrollment: | 42 |
Study Start Date: | March 2008 |
Estimated Study Completion Date: | December 2010 |
Estimated Primary Completion Date: | December 2010 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
Single arm: Experimental
Single arm (sunitinib arm) until PD, unacceptable toxicity, patients refused
|
Drug: sunitinib
sunitinib (50mg/day, 4weeks on, 2 weeks off) Repeat every 6 weeks. Treatment will continue until disease progression, unacceptable toxicity, or patients' refusal.
|
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Ji-Youn Han, M.D., Ph.D. | +82-31-920-1154 | jymama@ncc.re.kr |
Korea, Republic of, Gyeonggi-do | |
National Cancer Center, Korea | Recruiting |
Goyang-si, Gyeonggi-do, Korea, Republic of, 411-764 | |
Contact: Ji-Youn Han, M.D., Ph.D. +82-31-920-1154 jymama@ncc.re.kr | |
Principal Investigator: Ji-Youn Han, M.D. | |
Sub-Investigator: Jin Soo Lee, M.D. | |
Sub-Investigator: Heung Tae Kim, M.D. | |
Sub-Investigator: Tak Yun, M.D. | |
Sub-Investigator: Geon Kook Lee, M.D. | |
Sub-Investigator: Hyae Young Kim, M.D. |
Principal Investigator: | Ji-Youn Han, M.D.,Ph.D. | National Cancer Center, Korea |
Responsible Party: | National Cancer Center, Korea ( Jin Soo Lee ) |
Study ID Numbers: | NCCCTS-07-285 |
Study First Received: | January 25, 2008 |
Last Updated: | December 24, 2008 |
ClinicalTrials.gov Identifier: | NCT00620347 |
Health Authority: | South Korea: Korea Food and Drug Administration (KFDA) |
SCLC (small cell lung cancer) ED (extensive disease) RR (response rate) |
Disulfiram Thoracic Neoplasms Carcinoma, Neuroendocrine Carcinoma Neuroendocrine Tumors Carcinoma, Small Cell Neuroectodermal Tumors Respiratory Tract Diseases |
Sunitinib Lung Neoplasms Lung Diseases Neoplasms, Germ Cell and Embryonal Neuroepithelioma Adenocarcinoma Neoplasms, Glandular and Epithelial |
Respiratory Tract Neoplasms Neoplasms by Histologic Type Antineoplastic Agents Growth Substances Neoplasms, Nerve Tissue Physiological Effects of Drugs Angiogenesis Inhibitors |
Pharmacologic Actions Neoplasms Neoplasms by Site Therapeutic Uses Angiogenesis Modulating Agents Growth Inhibitors |